See more : Sports Toto Berhad (1562.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (603896.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhejiang Shouxiangu Pharmaceutical Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- iXensor Co., Ltd. (6734.TWO) Income Statement Analysis – Financial Results
- Alibaba Group Holding Limited (AHLA.DE) Income Statement Analysis – Financial Results
- CANDEAL Co.,Ltd (1446.T) Income Statement Analysis – Financial Results
- Mont Royal Resources Limited (MRZ.AX) Income Statement Analysis – Financial Results
- Theravance Biopharma, Inc. (TBPH) Income Statement Analysis – Financial Results
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (603896.SS)
About Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. researches, develops, and sells Chinese medicine products. It offers ganoderma lucidum spore powder, dendrobium officinale, crocus sativus, and other health products. The company was founded in 1997 and is based in Jinhua, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 784.35M | 829.07M | 767.14M | 636.05M | 546.76M | 511.45M | 369.96M | 314.88M | 301.91M | 301.59M | 253.03M | 177.75M |
| Cost of Revenue | 135.53M | 129.21M | 126.37M | 105.67M | 85.41M | 72.06M | 50.93M | 47.58M | 57.47M | 82.15M | 87.86M | 76.38M |
| Gross Profit | 648.82M | 699.86M | 640.76M | 530.38M | 461.35M | 439.39M | 319.03M | 267.30M | 244.45M | 219.44M | 165.17M | 101.37M |
| Gross Profit Ratio | 82.72% | 84.42% | 83.53% | 83.39% | 84.38% | 85.91% | 86.23% | 84.89% | 80.97% | 72.76% | 65.28% | 57.03% |
| Research & Development | 49.68M | 47.82M | 50.82M | 48.49M | 39.42M | 33.67M | 20.97M | 17.81M | 17.95M | 20.55M | 12.70M | 9.00M |
| General & Administrative | 43.93M | 37.19M | 35.67M | 44.99M | 58.98M | 53.09M | 18.39M | 12.44M | 12.01M | 13.91M | 33.11M | 23.37M |
| Selling & Marketing | 316.79M | 319.37M | 319.76M | 264.02M | 233.65M | 236.50M | 178.56M | 138.79M | 128.07M | 103.84M | 72.72M | 44.73M |
| SG&A | 360.73M | 356.57M | 355.43M | 309.01M | 292.63M | 289.59M | 196.95M | 151.24M | 140.08M | 117.75M | 105.83M | 68.11M |
| Other Expenses | -58.16M | 28.12M | 34.55M | 16.68M | 15.32M | -216.80K | -2.05M | 9.94M | 5.26M | 3.23M | 2.37M | 4.10M |
| Operating Expenses | 394.10M | 432.51M | 440.81M | 374.18M | 347.37M | 339.96M | 233.31M | 191.37M | 181.08M | 155.42M | 107.37M | 68.96M |
| Cost & Expenses | 529.62M | 561.71M | 567.18M | 479.85M | 432.77M | 412.02M | 284.24M | 238.94M | 238.55M | 237.58M | 195.24M | 145.34M |
| Interest Income | 48.09M | 25.45M | 24.16M | 11.51M | 3.33M | 1.90M | 600.48K | 24.62K | 125.91K | 196.59K | 0.00 | 0.00 |
| Interest Expense | 25.05M | 13.03M | 10.17M | 11.72M | 978.99K | 969.11K | 1.91M | 6.85M | 7.97M | 1.61M | 1.78M | 1.63M |
| Depreciation & Amortization | 99.99M | 81.08M | 65.83M | 54.70M | 49.13M | 47.07M | 39.88M | 114.07M | 35.42M | 20.84M | 8.32M | 1.40M |
| EBITDA | 379.58M | 372.71M | 278.36M | 220.73M | 175.67M | 158.29M | 131.16M | 202.54M | 98.54M | 87.55M | 60.98M | 33.67M |
| EBITDA Ratio | 48.39% | 43.08% | 34.69% | 32.93% | 30.65% | 29.64% | 34.46% | 40.33% | 35.22% | 29.64% | 24.10% | 18.13% |
| Operating Income | 254.72M | 280.88M | 207.15M | 158.90M | 127.77M | 110.30M | 90.84M | 71.01M | 57.50M | 66.45M | 52.65M | 30.83M |
| Operating Income Ratio | 32.48% | 33.88% | 27.00% | 24.98% | 23.37% | 21.57% | 24.55% | 22.55% | 19.04% | 22.03% | 20.81% | 17.34% |
| Total Other Income/Expenses | 188.56K | -2.91M | -6.09M | -5.20M | -2.78M | -216.80K | -2.05M | 9.94M | 5.13M | 3.08M | 2.37M | 2.49M |
| Income Before Tax | 254.91M | 277.97M | 201.06M | 153.70M | 124.99M | 110.09M | 88.79M | 80.93M | 62.62M | 69.53M | 55.02M | 34.90M |
| Income Before Tax Ratio | 32.50% | 33.53% | 26.21% | 24.17% | 22.86% | 21.52% | 24.00% | 25.70% | 20.74% | 23.05% | 21.74% | 19.63% |
| Income Tax Expense | 430.87K | 452.57K | 749.29K | 1.99M | 1.10M | 2.44M | -88.85K | -50.62K | -21.14K | 278.26K | 971.62K | 874.82K |
| Net Income | 254.48M | 277.78M | 200.83M | 151.71M | 123.90M | 107.65M | 88.88M | 80.98M | 62.64M | 69.25M | 54.05M | 34.02M |
| Net Income Ratio | 32.44% | 33.51% | 26.18% | 23.85% | 22.66% | 21.05% | 24.02% | 25.72% | 20.75% | 22.96% | 21.36% | 19.14% |
| EPS | 1.30 | 1.44 | 1.04 | 0.82 | 0.68 | 0.59 | 0.55 | 0.59 | 0.46 | 0.51 | 0.40 | 0.32 |
| EPS Diluted | 1.30 | 1.44 | 1.04 | 0.82 | 0.68 | 0.58 | 0.55 | 0.59 | 0.46 | 0.51 | 0.40 | 0.32 |
| Weighted Avg Shares Out | 195.75M | 192.54M | 193.59M | 184.32M | 183.03M | 181.74M | 162.72M | 136.72M | 135.73M | 136.40M | 104.93M | 104.93M |
| Weighted Avg Shares Out (Dil) | 195.75M | 192.54M | 193.59M | 184.32M | 183.03M | 184.14M | 162.74M | 136.72M | 135.73M | 136.40M | 104.93M | 104.93M |
No news found for: 603896.SS
Source: https://incomestatements.info
Category: Stock Reports